Hong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hong Chen has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Bin Su
Department of Oncology, 920th Hospital of Joint Logistics Support Force, 650032, Kunming, China
3 shared publicationsJun Zhu
Kunming Medical University, Kunming, Yunnan, China
3 shared publications- Yi Li
Kunming Medical University, Kunming, Yunnan, China
3 shared publications Yuanyuan Wang
Department of Pathology, 920th Hospital of Joint Logistics Support Force, Teaching Hospital of Kunming Medical University, Kunming, China
3 shared publicationsYuchi Mao
Department of Oncology, 920th Hospital of Joint Logistics Support Force, Teaching Hospital of Kunming Medical University, Kunming, China
3 shared publicationsGang Li
Kunming Medical University, Kunming, Yunnan, China
2 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1656375
Identification of a prognostic signature based on immunogenic adverse event-related genes to guide therapy for non-small cell lung cancer
Background: Immune checkpoint inhibitors (ICIs) improve outcomes in non−small cell lung cancer (NSCLC), yet reliable predictive biomarkers are still lacking. Given that immune−related adverse events (irAEs) often correlate with better ICI efficacy, this study aimed to develop and validate an irAE−related gene signature for risk stratification and treatment–response prediction in NSCLC. Methods: Transcriptomic and clinical data were obtained from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, designated as training and validation cohorts, respectively. Least absolute shrinkage and selection operator (LASSO) regression and Cox proportional hazards models were applied to identify eight irAE-associated genes for constructing a risk score (RS). Multivariate analyses evaluated differences in overall survival (OS), immunotherapy response, irAE incidence, immune escape potential, and tumor microenvironment (TME) profiles between high- and low-risk groups. Prognostic performance was validated using Kaplan–Meier curves, Cox regression, and receiver operating characteristic (ROC) analysis. A nomogram integrating RS with clinical factors was developed to improve prediction stability. Results: Via gene set variation analysis (GSVA) enrichment of 30 known immunologic gene sets in TCGA-LC, we stratified samples by immune score (cutoff = 0.23), identified 1,057 differentially expressed genes (DEGs) between groups, intersected with cancer-normal DEGs, and selected 132 irAE-related DEGs via Pearson correlation—genes functionally tied to T-cell activation and cytokine-mediated signaling pathways. LASSO–Cox regression derived an eight-gene prognostic signature demonstrating robust cross-cohort validation [area under the curve (AUC): TCGA = 0.770, GSE50081 = 0.767, GSE37745 = 0.758] and predictive accuracy for irAEs in GSE186143 (AUC = 0.807). In a validation NSCLC cohort ( n = 41), irAE occurrence correlated with superior clinical outcomes: objective response rate (87.50% vs . 44.00%), disease control rate (93.75% vs . 76.00%), median progression-free survival (20.0 vs . 9.9 months), and overall survival (21.4 vs . 12.1 months). Three key risk genes (POU2AF1, ANKRD44, CRTAM) showed significantly elevated protein expression levels and positive rates in irAE patients. High RS cohorts exhibited immunosuppressive TME characteristics and increased immune escape potential. A clinically relevant nomogram integrating RS with clinical factors (age, stage, and tumor recurrence) improved prognostic stability. Conclusions: Our irAE-associated gene signature robustly stratifies NSCLC patients for immunotherapy response and survival. Integrating RS with clinical parameters provides a practical tool to balance efficacy and safety.
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1656375
Open AccessIdentification of a prognostic signature based on immunogenic adverse event-related genes to guide therapy for non-small cell lung cancer
Background: Immune checkpoint inhibitors (ICIs) improve outcomes in non−small cell lung cancer (NSCLC), yet reliable predictive biomarkers are still lacking. Given that immune−related adverse events (irAEs) often correlate with better ICI efficacy, this study aimed to develop and validate an irAE−related gene signature for risk stratification and treatment–response prediction in NSCLC. Methods: Transcriptomic and clinical data were obtained from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, designated as training and validation cohorts, respectively. Least absolute shrinkage and selection operator (LASSO) regression and Cox proportional hazards models were applied to identify eight irAE-associated genes for constructing a risk score (RS). Multivariate analyses evaluated differences in overall survival (OS), immunotherapy response, irAE incidence, immune escape potential, and tumor microenvironment (TME) profiles between high- and low-risk groups. Prognostic performance was validated using Kaplan–Meier curves, Cox regression, and receiver operating characteristic (ROC) analysis. A nomogram integrating RS with clinical factors was developed to improve prediction stability. Results: Via gene set variation analysis (GSVA) enrichment of 30 known immunologic gene sets in TCGA-LC, we stratified samples by immune score (cutoff = 0.23), identified 1,057 differentially expressed genes (DEGs) between groups, intersected with cancer-normal DEGs, and selected 132 irAE-related DEGs via Pearson correlation—genes functionally tied to T-cell activation and cytokine-mediated signaling pathways. LASSO–Cox regression derived an eight-gene prognostic signature demonstrating robust cross-cohort validation [area under the curve (AUC): TCGA = 0.770, GSE50081 = 0.767, GSE37745 = 0.758] and predictive accuracy for irAEs in GSE186143 (AUC = 0.807). In a validation NSCLC cohort ( n = 41), irAE occurrence correlated with superior clinical outcomes: objective response rate (87.50% vs . 44.00%), disease control rate (93.75% vs . 76.00%), median progression-free survival (20.0 vs . 9.9 months), and overall survival (21.4 vs . 12.1 months). Three key risk genes (POU2AF1, ANKRD44, CRTAM) showed significantly elevated protein expression levels and positive rates in irAE patients. High RS cohorts exhibited immunosuppressive TME characteristics and increased immune escape potential. A clinically relevant nomogram integrating RS with clinical factors (age, stage, and tumor recurrence) improved prognostic stability. Conclusions: Our irAE-associated gene signature robustly stratifies NSCLC patients for immunotherapy response and survival. Integrating RS with clinical parameters provides a practical tool to balance efficacy and safety.
- Open Access
- 8 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1718918
Sequential anlotinib and camrelizumab combination therapy achieves exceptional survival in multi-driver mutated, TMB-low/PD-L1-low/MSS pulmonary sarcomatoid carcinoma: case report and literature review
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) whose molecular characteristics and therapeutic strategies remain poorly defined. This case report documents an exceptional 72-month overall survival in a 40-year-old male patient with stage IVa pulmonary sarcomatoid carcinoma (PSC). The patient harbored seven coexisting driver mutations [ ROS1 , RET(exon16,exon19) , TSC2 , ALK , STK11 , PTEN ] and exhibited triple-negative immunosuppressive biomarkers: low PD-L1 expression (TPS 3%), low tumor mutational burden (TMB, 11mut/Mb), and microsatellite stable (MSS) status. Sequential anlotinib (anti-angiogenic drug) and camrelizumab (PD-1 inhibitor) combination therapy overcame three biological barriers: (1) angiogenesis inhibition reversed PD-L1 primary resistance by remodeling the tumor microenvironment; (2) treatment induced neoantigens bypassed TMB-L/MSS limitations; (3) multi-target synergy against seven driver mutations. This approach resulted in unprecedented survival outcomes: the 72-month overall survival dramatically exceeds the median OS of less than 12 months reported for advanced PSC, and the patient maintained a progression-free survival of over 37 months on combination therapy, surpassing historical PFS benchmarks. This case provides a clinically actionable framework for managing multi-driver mutated, immunoresistant PSC.
- 8 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1718918
Open AccessSequential anlotinib and camrelizumab combination therapy achieves exceptional survival in multi-driver mutated, TMB-low/PD-L1-low/MSS pulmonary sarcomatoid carcinoma: case report and literature review
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) whose molecular characteristics and therapeutic strategies remain poorly defined. This case report documents an exceptional 72-month overall survival in a 40-year-old male patient with stage IVa pulmonary sarcomatoid carcinoma (PSC). The patient harbored seven coexisting driver mutations [ ROS1 , RET(exon16,exon19) , TSC2 , ALK , STK11 , PTEN ] and exhibited triple-negative immunosuppressive biomarkers: low PD-L1 expression (TPS 3%), low tumor mutational burden (TMB, 11mut/Mb), and microsatellite stable (MSS) status. Sequential anlotinib (anti-angiogenic drug) and camrelizumab (PD-1 inhibitor) combination therapy overcame three biological barriers: (1) angiogenesis inhibition reversed PD-L1 primary resistance by remodeling the tumor microenvironment; (2) treatment induced neoantigens bypassed TMB-L/MSS limitations; (3) multi-target synergy against seven driver mutations. This approach resulted in unprecedented survival outcomes: the 72-month overall survival dramatically exceeds the median OS of less than 12 months reported for advanced PSC, and the patient maintained a progression-free survival of over 37 months on combination therapy, surpassing historical PFS benchmarks. This case provides a clinically actionable framework for managing multi-driver mutated, immunoresistant PSC.
- Open Access
- 30 January 2024
- Published by Springer Nature in Research Square
Research on developing a predictive model for radiation pneumonitis risk based on radiomics and multiparameters
Objective A Nomogram model was constructed by combined pre-treatment CT radiomics, clinical characteristics, and lung dosimetry data of patients with non-small cell lung cancer,and to explore its predictive value of radiation pneumonitis. Methods A retrospective analysis was conducted on 104 non-surgical NSCLC patients who underwent chest intensity modulated radiation therapy(IMRT) at our center from January 2013 to December 2017. Intratumoral and peritumoral radiomics models were established using pre-radiotherapy CT images, and logistic regression was used to screen for the best clinical and dosimetric parameters. A combined Nomogram model was established by the above parameters, and receiver operating characteristic curve (ROC) analysis and area under the curve (AUC) was performed to estimate its predictive efficacy of radiation pneumonia. Results Among 104 patients, 59 cases developed radiopneumonia and 45 cases did not suffer from radiopneumonia within 6 months after radiotherapy, which were divided into 73 cases in the training set and 31 cases in the validation set. The AUC values of the intratumoral radiomics group model in the training and validation sets were 0.871 (95%CI 0.771~0.938) and 0.719 (95%CI 0.400~0.952), respectively, and the predictive efficacy was better than that of the peritumoral radiomics group model [0.798 (95%CI 0.629~0.921) and 0.714 (95%CI 0.500 ~0.857)]. Multifactorial regression analysis showed that patients' age, smoking, and pre-radiotherapy lymphocyte ratio were associated with radiation pneumonitis (P20Gy were associated with radiation pneumonitis (P20Gy has a better predictive accuracy for radiation pneumonitis in NSCLC, and it can be used as a quantitative model for the prediction of radiation pneumonitis in patients undergoing radiotherapy for NSCLC.
- 30 January 2024
- Published by Springer Nature in Research Square
Open AccessResearch on developing a predictive model for radiation pneumonitis risk based on radiomics and multiparameters
Objective A Nomogram model was constructed by combined pre-treatment CT radiomics, clinical characteristics, and lung dosimetry data of patients with non-small cell lung cancer,and to explore its predictive value of radiation pneumonitis. Methods A retrospective analysis was conducted on 104 non-surgical NSCLC patients who underwent chest intensity modulated radiation therapy(IMRT) at our center from January 2013 to December 2017. Intratumoral and peritumoral radiomics models were established using pre-radiotherapy CT images, and logistic regression was used to screen for the best clinical and dosimetric parameters. A combined Nomogram model was established by the above parameters, and receiver operating characteristic curve (ROC) analysis and area under the curve (AUC) was performed to estimate its predictive efficacy of radiation pneumonia. Results Among 104 patients, 59 cases developed radiopneumonia and 45 cases did not suffer from radiopneumonia within 6 months after radiotherapy, which were divided into 73 cases in the training set and 31 cases in the validation set. The AUC values of the intratumoral radiomics group model in the training and validation sets were 0.871 (95%CI 0.771~0.938) and 0.719 (95%CI 0.400~0.952), respectively, and the predictive efficacy was better than that of the peritumoral radiomics group model [0.798 (95%CI 0.629~0.921) and 0.714 (95%CI 0.500 ~0.857)]. Multifactorial regression analysis showed that patients' age, smoking, and pre-radiotherapy lymphocyte ratio were associated with radiation pneumonitis (P20Gy were associated with radiation pneumonitis (P20Gy has a better predictive accuracy for radiation pneumonitis in NSCLC, and it can be used as a quantitative model for the prediction of radiation pneumonitis in patients undergoing radiotherapy for NSCLC.
- Open Access
- 7 April 2022
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 41 (1) , 1-16
Mouse mesenchymal stem cell-derived exosomal miR-466f-3p reverses EMT process through inhibiting AKT/GSK3β pathway via c-MET in radiation-induced lung injury
Background: Radiation-induced lung fibrosis (RILF) is a common complication of thoracic radiotherapy. Alveolar epithelial cells play a crucial role in lung fibrosis via epithelial-mesenchymal transition (EMT). Exosomes derived from mesenchymal stem cells own the beneficial properties to repair and regeneration of damaged tissues, however the underlying mechanisms remain poorly understood. Methods: Mouse mesenchymal stem cells-derived exosomes (mMSCs-Exo) were isolated by differential centrifugation, and their protective effects were assessed in vivo and in vitro, respectively. EMT-associated proteins were measured via western blot assay and/or immunofluorescence staining. The miRNA expression was measured by microarray assay and qPCR. Furthermore, bioinformatics prediction with KEGG analysis, luciferase assay, and rescue experiments were performed to explore the molecular mechanism underlying miR-466f-3p. Results: mMSCs-Exos were efficiently isolated ranging from 90-150 nm with high expression of exosomal markers (CD63, TSG101, and CD9). mMSCs-Exos administration efficiently relieved radiation-induced lung injury with less collagen deposition and lower levels of IL-1β and IL-6. Meanwhile, in vitro results showed mMSCs-Exos treatment obviously reversed EMT process induced by radiation. Among enriched miRNA cargo in exosomes, miR-466f-3p was primarily responsible for the protective effects via inhibition of AKT/GSK3β pathway. Our mechanistic study further demonstrated that c-MET was the direct target of miR-466f-3p, whose restoration partially abrogated mMSCs-Exo-mediated inhibition in both EMT process and AKT/GSK3β signaling activity induced by radiation. Conclusions: Our findings indicated that exosomal miR-466f-3p derived from mMSCs may possess anti-fibrotic properties and prevent radiation-induced EMT through inhibition of AKT/GSK3β via c-MET, providing a promising therapeutic modality for radiation-induced lung fibrosis.
- 7 April 2022
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 41 (1) , 1-16
Open AccessMouse mesenchymal stem cell-derived exosomal miR-466f-3p reverses EMT process through inhibiting AKT/GSK3β pathway via c-MET in radiation-induced lung injury
Background: Radiation-induced lung fibrosis (RILF) is a common complication of thoracic radiotherapy. Alveolar epithelial cells play a crucial role in lung fibrosis via epithelial-mesenchymal transition (EMT). Exosomes derived from mesenchymal stem cells own the beneficial properties to repair and regeneration of damaged tissues, however the underlying mechanisms remain poorly understood. Methods: Mouse mesenchymal stem cells-derived exosomes (mMSCs-Exo) were isolated by differential centrifugation, and their protective effects were assessed in vivo and in vitro, respectively. EMT-associated proteins were measured via western blot assay and/or immunofluorescence staining. The miRNA expression was measured by microarray assay and qPCR. Furthermore, bioinformatics prediction with KEGG analysis, luciferase assay, and rescue experiments were performed to explore the molecular mechanism underlying miR-466f-3p. Results: mMSCs-Exos were efficiently isolated ranging from 90-150 nm with high expression of exosomal markers (CD63, TSG101, and CD9). mMSCs-Exos administration efficiently relieved radiation-induced lung injury with less collagen deposition and lower levels of IL-1β and IL-6. Meanwhile, in vitro results showed mMSCs-Exos treatment obviously reversed EMT process induced by radiation. Among enriched miRNA cargo in exosomes, miR-466f-3p was primarily responsible for the protective effects via inhibition of AKT/GSK3β pathway. Our mechanistic study further demonstrated that c-MET was the direct target of miR-466f-3p, whose restoration partially abrogated mMSCs-Exo-mediated inhibition in both EMT process and AKT/GSK3β signaling activity induced by radiation. Conclusions: Our findings indicated that exosomal miR-466f-3p derived from mMSCs may possess anti-fibrotic properties and prevent radiation-induced EMT through inhibition of AKT/GSK3β via c-MET, providing a promising therapeutic modality for radiation-induced lung fibrosis.
- Open Access
- 20 October 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (10) , 1-14
Upregulation of KCNQ1OT1 promotes resistance to stereotactic body radiotherapy in lung adenocarcinoma by inducing ATG5/ATG12-mediated autophagy via miR-372-3p
Stereotactic body radiotherapy (SBRT) has emerged as a standard treatment for non-small-cell lung cancer. However, its therapeutic advantages are limited with the development of SBRT resistance. The SBRT-resistant cell lines (A549/IR and H1975/IR) were established after exposure with hypofractionated irradiation. The differential lncRNAs were screened by microarray assay, then the expression was detected in LUAD tumor tissues and cell lines by qPCR. The influence on radiation response was assessed via in vitro and in vivo assays, and autophagy levels were evaluated by western blot and transmission electron microscopy. Bioinformatics prediction and rescue experiments were used to identify the pathways underlying SBRT resistance. High expression of KCNQ1OT1 was identified in LUAD SBRT-resistant cells and tissues, positively associated with a large tumor, advanced clinical stage, and a lower response rate to concurrent therapy. KCNQ1OT1 depletion significantly resensitized A549/IR and H1975/IR cells to radiation by inhibiting autophagy, which could be attenuated by miR-372-3p knockdown. Furthermore, autophagy-related 5 (ATG5) and autophagy-related 12 (ATG12) were confirmed as direct targets of miR-372-3p. Restoration of either ATG5 or ATG12 abrogated miR-372-3p-mediated autophagy inhibition and radiosensitivity. Our data describe that KCNQ1OT1 is responsible for SBRT resistance in LUAD through induction of ATG5- and ATG12-dependent autophagy via sponging miR-372-3p, which would be a potential strategy to enhance the antitumor effects of radiotherapy in LUAD.
- 20 October 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (10) , 1-14
Open AccessUpregulation of KCNQ1OT1 promotes resistance to stereotactic body radiotherapy in lung adenocarcinoma by inducing ATG5/ATG12-mediated autophagy via miR-372-3p
Stereotactic body radiotherapy (SBRT) has emerged as a standard treatment for non-small-cell lung cancer. However, its therapeutic advantages are limited with the development of SBRT resistance. The SBRT-resistant cell lines (A549/IR and H1975/IR) were established after exposure with hypofractionated irradiation. The differential lncRNAs were screened by microarray assay, then the expression was detected in LUAD tumor tissues and cell lines by qPCR. The influence on radiation response was assessed via in vitro and in vivo assays, and autophagy levels were evaluated by western blot and transmission electron microscopy. Bioinformatics prediction and rescue experiments were used to identify the pathways underlying SBRT resistance. High expression of KCNQ1OT1 was identified in LUAD SBRT-resistant cells and tissues, positively associated with a large tumor, advanced clinical stage, and a lower response rate to concurrent therapy. KCNQ1OT1 depletion significantly resensitized A549/IR and H1975/IR cells to radiation by inhibiting autophagy, which could be attenuated by miR-372-3p knockdown. Furthermore, autophagy-related 5 (ATG5) and autophagy-related 12 (ATG12) were confirmed as direct targets of miR-372-3p. Restoration of either ATG5 or ATG12 abrogated miR-372-3p-mediated autophagy inhibition and radiosensitivity. Our data describe that KCNQ1OT1 is responsible for SBRT resistance in LUAD through induction of ATG5- and ATG12-dependent autophagy via sponging miR-372-3p, which would be a potential strategy to enhance the antitumor effects of radiotherapy in LUAD.
- Open Access
- 18 April 2019
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 298
Upregulation of miR-214 Induced Radioresistance of Osteosarcoma by Targeting PHLDA2 via PI3K/Akt Signaling
Osteosarcoma is an aggressive bone tumor with high resistance to radiotherapy. Pleckstrin homology-like domain family A member 2 (PHLDA2) displays low expression in human osteosarcoma as a proapoptosis factor. miRNAs have been shown to be important in modulating translation and therapeutic responsiveness in solid tumors. Herein, we used luciferase assay to show that miR-214 downregulates the PHLDA2 expression by targeting its 3′-untranslated region (UTR). A high level of miR-214 was identified in tumor tissues from 30 osteosarcoma patients via qPCR analysis, associated positively with lung metastasis. Ectopic expression miR-214 enhanced radioresistance in osteosarcoma cells, with decreased IR-induced apoptosis. Moreover, the depletion of miR-214 enhanced radiosensitivity in both osteosarcoma cells and mouse xenograft models. Importantly, we showed that miR-214 regulated the activation of phosphatidylinositol-3-kinase/Akt signaling pathway by inhibiting PHLDA2. Finally, the introduction of PHLDA2 cDNA lacking the 3′-UTR or treatment with Akt inhibitor LY294002 partially abrogated miR-214-induced radioresistance. In summary, our results reveal that the upregulation of miR-214 as a frequent event in osteosarcoma contributes to radioresistance by regulating the PHLDA2/Akt pathway. The miR-214/PHLDA2/Akt axis provides a new avenue toward understanding the mechanism of radiosensitivity and may be a potential target for osteosarcoma intervention.
- 18 April 2019
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 298
Open AccessUpregulation of miR-214 Induced Radioresistance of Osteosarcoma by Targeting PHLDA2 via PI3K/Akt Signaling
Osteosarcoma is an aggressive bone tumor with high resistance to radiotherapy. Pleckstrin homology-like domain family A member 2 (PHLDA2) displays low expression in human osteosarcoma as a proapoptosis factor. miRNAs have been shown to be important in modulating translation and therapeutic responsiveness in solid tumors. Herein, we used luciferase assay to show that miR-214 downregulates the PHLDA2 expression by targeting its 3′-untranslated region (UTR). A high level of miR-214 was identified in tumor tissues from 30 osteosarcoma patients via qPCR analysis, associated positively with lung metastasis. Ectopic expression miR-214 enhanced radioresistance in osteosarcoma cells, with decreased IR-induced apoptosis. Moreover, the depletion of miR-214 enhanced radiosensitivity in both osteosarcoma cells and mouse xenograft models. Importantly, we showed that miR-214 regulated the activation of phosphatidylinositol-3-kinase/Akt signaling pathway by inhibiting PHLDA2. Finally, the introduction of PHLDA2 cDNA lacking the 3′-UTR or treatment with Akt inhibitor LY294002 partially abrogated miR-214-induced radioresistance. In summary, our results reveal that the upregulation of miR-214 as a frequent event in osteosarcoma contributes to radioresistance by regulating the PHLDA2/Akt pathway. The miR-214/PHLDA2/Akt axis provides a new avenue toward understanding the mechanism of radiosensitivity and may be a potential target for osteosarcoma intervention.
- 29 January 2014
- Published by Springer Nature in Tumor Biology
- Vol. 35 (5) , 4831-4839
Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells
- 29 January 2014
- Published by Springer Nature in Tumor Biology
- Vol. 35 (5) , 4831-4839
Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells